Eli Lilly to Acquire Merida Biosciences for Up to $2.88 Billion
Eli Lilly has agreed to purchase biotech firm Merida Biosciences in a cash deal valued at up to $2.88 billion. The acquisition is designed to accelerate the development of novel therapies targeting serious autoimmune and allergic conditions.
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (59/100)Sources
Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push - Reuters
Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push Reuters
Read full article →Eli Lilly to Buy Merida Biosciences for Up to $2.875 Billion - WSJ
Eli Lilly to Buy Merida Biosciences for Up to $2.875 Billion WSJ
Read full article →Eli Lilly to buy Merida Biosciences in deal worth up to $2.88 billion
Eli Lilly plans to buy privately held Merida Biosciences for up to $2.88 billion in cash.
Read full article →Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What It Means for the Stock. - Barron's
Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What It Means for the Stock. Barron's
Read full article →Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases - Morningstar
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases Morningstar
Read full article →Lilly to buy Merida Biosciences for up to $2.875B in cash
Read full article →Lilly to acquire Merida Biosciences for up to $2.875 billion
By Investing.com
Read full article →Coverage Timeline
Related Stories
Glacier Bancorp Appoints Byron Pollan as New Chief Financial Officer
27m ago
Prediction Platform Kalshi Bans Former Congressman George Santos for Life
44m ago
U.S. Treasury Yields Surge as Fed Official Signals Support for Rate Hike
1h ago
Dell Stock Gains Investor Focus Ahead of September Earnings Report
1h ago